IGCS19-0266

79 **PRE-BRACHYTHERAPY MAGNETIC RESONANCE-BASED 3D TUMOR VOLUME EVALUATION FOR OUTCOME PREDICTION IN CERVICAL CANCER PATIENTS TREATED WITH DEFINITIVE CHEMORADIATION**

¹C El Khoury*, ²D Atallah, ³J Naba, ³A Nassar, ²M Moubarak, ¹F Azoury, ¹T Felefly, ¹J El Barouky, ¹R Sayah, ¹D Nasr, ⁴G Chahine, ¹E Nasr. ¹University of Saint Joseph, Hotel Dieu de France – Department of Radiation Oncology, Beirut, Lebanon; ²University of Saint Joseph, Hotel Dieu de France – Department of Gynecology – Division of Gynecologic Oncology, Beirut, Lebanon; ³University of Saint Joseph, School of Medicine, Beirut, Lebanon; ⁴University of Saint Joseph, Hotel Dieu de France – Department of Medical Oncology, Beirut, Lebanon

10.1136/ijgc-2019-IGCS.79

Objectives To report the impact on survival of residual tumor volume (RTV) prior to brachytherapy (BT) initiation determined by magnetic resonance imaging (MRI) in patients treated for locally advanced cervical cancer with definitive chemoradiotherapy (CRT).

Methods MRI examinations were prospectively performed in patients with advanced cervical cancer (Stages IB2-IVA) after CRT completion and prior to BT initiation. RTV was delineated on each T2-weighted slice and volumetry was derived on the treatment planning system. All patients received external beam radiation (EBRT) with concomitant Cisplatin followed by volume-based BT planning. Cumulative EBRT and BT doses were calculated as the total equivalent dose in 2 Gy fractions (EQD2). Potential prognostic factors were selected based on non-parametric tests and then analyzed for survival with a Cox regression model.

Results Median post-therapy follow-up was 27.4 months (range, 3–57.8). Thirty-seven patients were included. According to the FIGO classification, 8% were stage IB, 75% stage II, 11% stage III, and 6% stage IV. Overall survival was 86.5%. Of the patients evaluated, 29.7% had complete remission on pre-BT MRI and 18.9% were considered having local failure or distant disease. At bivariate analysis, RTV >2 mL, D90 CTV-HR <84 Gy and excessive treatment time were all predictors of poor overall survival. At multivariate regression analysis, only RTV persisted as a significant prognostic factor with survival rates of 95.8% and 69.2% for pre-BT RTV ≤2 mL and >2 mL respectively (p=0.005).

Conclusions Our preliminary data suggest that pre-BT RTV >2 mL is a predictor of poor survival.

IGCS19-0195

80 **SMARCA4 INACTIVATION DEFINES A SUBSET OF UNDIFFERENTIATED UTERINE SARCOMAS WITH RHABDOID AND SMALL CELL FEATURES AND GERMLINE MUTATION ASSOCIATION**

¹D Lin*, ²J Allen, ³J Hecht, ¹J Killian, ¹N Ngo, ¹C Edgerly, ¹E Severson, ⁴S Ali, ²R Erlich, ¹S Ramkissoon, ¹JA Vergilio, ¹J Ross, ¹J Elvin. ¹Foundation Medicine, Pathology, Cambridge, USA; ²Foundation Medicine, Biomedical Informatics, Cambridge, USA; ³Beth Israel Deaconess Medical Center, Pathology, Boston, USA; ⁴Foundation Medicine, Clinical Development, Cambridge, USA

10.1136/ijgc-2019-IGCS.80

Objectives A rare subset of aggressive SMARCA4-deficient uterine sarcomas (SMARCA4-DUS) has been recently proposed,

with only a limited number of cases having been previously described. Since potential targeted therapies exist for SMARCA4-deficient tumors, we sought to validate and expand the clinicopathological and molecular features of SMARCA4-DUS.

Methods A retrospective database search of a large, CLIA-certified and CAP-accredited, reference molecular laboratory was performed for clinically advanced uterine sarcomas with genomic profiles that contained SMARCA4 mutations. Clinicopathological data were extracted from patient records. Morphological and molecular features were centrally reviewed.

Results Here, we identify and describe the clinicopathological and genomic features of 17 additional cases of SMARCA4-DUS. Median patient age was 51 years (range 33–70). Most tumors were aggressive with distant metastasis. SMARCA4-DUS demonstrated predominantly rhabdoid or large epithelioid cells with abundant cytoplasm, but also had varying degrees of small cell and spindle cell morphology. Tumors were microsatellite stable and exhibited no other or only few co-occurring genomic alterations by comprehensive genomic profiling. We discovered one patient, who developed SMARCA4-DUS at age of 55, had a germline SMARCA4 mutation, whose daughter had previously died of small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), at the age of 32.

Conclusions Our data support the notion that SMARCA4 inactivation is the driver oncogenic event of a morphologically and molecularly distinct form of uterine sarcoma. Identification of SMARCA4-DUS may be clinically important due to their aggressive behavior, germline association and emerging targeted therapies.

Poster Discussion with the Professor Station 2

IGCS19-0473

81 **ATTITUDE TOWARDS AND FACTORS AFFECTING UPTAKE OF POPULATION BASED BRCA TESTING IN ASHKENAZI JEWS: A COHORT STUDY**

¹R Manchanda*, ²M Burnell, ¹F Gaba, ³S Sanderson, ⁴K Loggenberg, ⁵S Gessler, ³J Wardle, ⁶L Side, ⁵R Desai, ⁷A Brady, ⁸H Dorkins, ⁹Y Wallis, ¹⁰C Chapman, ¹¹C Jacobs, ¹²I Tomlinson, ¹³U Beller, ²U Menon, ¹⁴I Jacobs. ¹Queen Mary University of London and Barts Health NHS Trust, Barts Cancer Institute, London, UK; ²University College London, MRC Clinical Trials Unit, London, UK; ³University College London, Behavioral Sciences Unit- Department of Epidemiology and Public Health, London, UK; ⁴Great Ormond Street Hospital, North East Thames Regional Genetics Service, London, UK; ⁵University College London, Department of Womens Cancer, London, UK; ⁶University Hospital Southampton NHS Foundation Trust, Clinical Genetics, Southampton, UK; ⁷Northwick Park Hospital, Dept Clinical Genetics- North West Thames Regional Genetics Unit, London, UK; ⁸University of Oxford, St Peter's College, Oxford, UK; ⁹Birmingham Women's NHS Foundation Trust, West Midlands Regional Genetics Laboratory, Birmingham, UK; ¹⁰Birmingham Women's NHS Foundation Trust, Dept Clinical Genetics- West Midlands Regional Genetics Service, Birmingham, UK; ¹¹University of Technology Sydney, Genetics, Sydney, Australia; ¹²University of Birmingham, Institute of Cancer and Genomic Sciences, Birmingham, UK; ¹³Shaare Zedek Medical Center, Department of Gynaecology, Jerusalem, Israel; ¹⁴University of New South Wales, Chancellery Building, Sydney, Australia

10.1136/ijgc-2019-IGCS.81

Objectives To evaluate the factors affecting interest, intention, uptake, and attitude towards unselected population-based BRCA-testing in the Ashkenazi Jewish (AJ) population.